TabletsClinical Overview
Ivabradine Hydrochloride is a hyperpolarization-activated cyclic nucleotide-gated (HCN) channel blocker on the WHO Model List of Essential Medicines. It selectively and specifically inhibits the cardiac pacemaker If ("funny") current in the sinoatrial node, slowing diastolic depolarization and reducing resting and exercise heart rates in a dose-dependent manner without affecting ventricular repolarization, myocardial contractility, intracardiac conduction, or blood pressure. Indicated for chronic heart failure with reduced ejection fraction (HFrEF, NYHA II-IV, LVEF <= 35%, sinus rhythm, HR >= 70 bpm) and symptomatic management of chronic stable angina.
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
Take orally twice daily with meals (morning and evening) with water. Taking with food delays absorption and provides consistent exposure. Maintain regular pulse rate monitoring.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Phosphenes (luminous visual phenomena/transient visual brightness triggered by sudden light changes, due to retinal Ih channel inhibition), bradycardia, first-degree AV block, headache, dizziness. Rare/Severe: Severe bradycardia, sinus arrest, atrial fibrillation, and QT prolongation secondary to bradycardia.
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
Patient must be in sinus rhythm (not effective in atrial fibrillation). Contraindicated in resting heart rate < 70 bpm prior to treatment, cardiogenic shock, acute myocardial infarction, severe hepatic impairment, and concurrent strong CYP3A4 inhibitors. Monitor regularly for development of atrial fibrillation.
Schedule H (Prescription Required)
This medication is scheduled under statutory drug regulatory frameworks (CDSCO / Drugs & Cosmetics Rules). Dispensing requires a valid medical prescription from a registered medical practitioner. Self-medication or unsupervised dosage adjustment carries significant clinical risks.
Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, clinical diagnosis, or treatment recommendations. Always consult a registered medical practitioner or qualified cardiologist/pharmacist before initiating, altering, or substituting any cardiovascular medication.